TG Therapeutics Inc
$ 30.51
-0.20%
24 Feb - close price
- Market Cap 4,853,277,000 USD
- Current Price $ 30.51
- High / Low $ 31.08 / 30.15
- Stock P/E 11.04
- Book Value 4.26
- EPS 2.77
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 1.12 %
- 52 Week High 46.48
- 52 Week Low 25.28
About
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Analyst Target Price
$44.43
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-08 | 2025-04-29 | 2025-02-26 | 2024-11-04 | 2024-08-06 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-01 | 2023-05-01 | 2023-02-28 |
| Reported EPS | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 | -0.07 | -0.1 | 0.73 | -0.34 | -0.28 | -0.39 |
| Estimated EPS | 0.22 | 0.19 | 0.174 | 0.09 | 0.03 | -0.05 | -0.04 | -0.1 | 0.12 | -0.25 | -0.37 | -0.26 |
| Surprise | 2.21 | -0.02 | -0.144 | 0.06 | -0.01 | 0.09 | -0.03 | 0 | 0.61 | -0.09 | 0.09 | -0.13 |
| Surprise Percentage | 1004.5455% | -10.5263% | -82.7586% | 66.6667% | -33.3333% | 180% | -75% | 0% | 508.3333% | -36% | 24.3243% | -50% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.35 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TGTX
2026-02-23 16:28:35
TG Therapeutics (TGTX) is anticipated to report a significant year-over-year increase in earnings and revenue for the quarter ending December 2025. Despite an upward revision in revenue estimates, the consensus EPS estimate has been revised lower, and the company currently has a negative Earnings ESP of -12.43% coupled with a Zacks Rank of #3, making a definitive earnings beat prediction difficult. Investors should also consider other factors beyond earnings surprise history.
2026-02-23 12:55:19
TG Therapeutics will host a conference call on February 26, 2026, to discuss its financial results for the fourth quarter and full year 2025, and to provide a business outlook for 2026. CEO Michael S. Weiss will lead the call, which will be accessible via phone and webcast. The company, known for its FDA-approved drug BRIUMVI® for multiple sclerosis, will issue a press release with financial details before the call.
2026-02-23 12:21:48
TG Therapeutics (NASDAQ: TGTX) announced it will host a conference call on Thursday, February 26, 2026, at 8:30 AM ET to discuss its fourth quarter and full year 2025 financial results and provide a business outlook for 2026. Chairman and CEO Michael S. Weiss will host the call, which will also be available via live webcast and replay on the company's website. The company will release its financial results in a press release prior to the call.
2026-02-22 23:33:28
The UNITY-CLL study, presented at ASH 2020, demonstrated that the combination of ublituximab and Ukoniq (U2) significantly prolonged progression-free survival in patients with treatment-naive or relapsed/refractory Chronic Lymphocytic Leukemia (CLL) compared to obinutuzumab plus chlorambucil. U2 also showed higher overall response rates across various patient subgroups. While associated with some serious side effects like elevated liver enzymes and colitis, TG Therapeutics Inc has submitted a biologics license application to the FDA based on these promising results.
2026-02-20 13:16:43
Persistent Asset Partners Ltd significantly reduced its stake in TG Therapeutics, Inc. ($TGTX) by selling 71,539 shares, decreasing their holdings by 83.6% to 14,041 shares valued at $507,000. Other institutional investors like Public Sector Pension Investment Board and Jump Financial LLC either increased their positions or initiated new ones. The article also covers the company's stock performance, insider trading activity, and recent analyst ratings, which currently average a "Moderate Buy" with a consensus price target of $50.00.
2026-02-19 18:57:11
TG Therapeutics (TGTX) is being re-evaluated after releasing five-year data for its BRIUMVI multiple sclerosis treatment, showing durable efficacy and safety. Despite a recent share price decline, the stock has a three-year return of 72.96% and is considered "Undervalued" by Simply Wall St with a fair value of $44.43. The company's valuation relies on accelerating revenue from BRIUMVI and strong market penetration, though rising competition and potential setbacks pose risks.
